Skip to main content
Top
Published in: International Journal of Legal Medicine 2/2009

01-03-2009 | Original Article

Prevalence of adverse drug combinations in a large post-mortem toxicology database

Authors: Terhi Launiainen, Erkki Vuori, Ilkka Ojanperä

Published in: International Journal of Legal Medicine | Issue 2/2009

Login to get access

Abstract

The prevalence of important adverse drug combinations was studied among the 37,367 cases included in the Finnish post-mortem toxicology database during 2000–2006. The new SFINX interaction database (Swedish, Finnish, INteraction X-referencing) was utilised to identify adverse drug combinations. Consequently, the 24 drugs chosen for the study generated 96 two-compound combinations possessing potentially severe interactions. The total number of hits for the combinations found in the post-mortem database was 267, which accounts for approximately 0.71% of all cases. The potential role of adverse drug interaction (ADI) in these cases was evaluated from the background information and death certificate. The possible ADI cases comprised 23% of all hits and 0.17% of all cases analysed. In cases with a pharmacodynamic mechanism, the most prominent combinations were medicines causing serotonin syndrome or a β1-blocker with verapamil or diltiazem. In cases with a pharmacokinetic mechanism, half of the cases involved digoxin in combination with verapamil. In one third of the possible ADI cases, a forensic pathologist had noted the studied compounds as an underlying or contributing cause of death, although the agents’ specific role in ADIs was rarely recognised.
Appendix
Available only for authorised users
Literature
1.
go back to reference Beijer HJM, de Blaey CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24:46–54PubMedCrossRef Beijer HJM, de Blaey CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24:46–54PubMedCrossRef
2.
go back to reference Mozayani A, Raymon LP (eds) (2003) Handbook of drug interactions. A clinical and forensic guide. Humana, Totowa, NJ Mozayani A, Raymon LP (eds) (2003) Handbook of drug interactions. A clinical and forensic guide. Humana, Totowa, NJ
3.
go back to reference Baxter K (ed) (2005) Stockley’s drug interactions, 7th edn. Pharmaceutical Press, London, UK Baxter K (ed) (2005) Stockley’s drug interactions, 7th edn. Pharmaceutical Press, London, UK
4.
go back to reference Lampela P, Hartikainen S, Sulkava R, Huupponen R (2007) Adverse drug effects in elderly people—a disparity between clinical examination and adverse effects self-reported by the patient. Eur J Clin Pharmacol 63:509–515PubMedCrossRef Lampela P, Hartikainen S, Sulkava R, Huupponen R (2007) Adverse drug effects in elderly people—a disparity between clinical examination and adverse effects self-reported by the patient. Eur J Clin Pharmacol 63:509–515PubMedCrossRef
5.
go back to reference Öhberg A, Vuori E, Ojanperä I, Lönnqvist J (1996) Alcohol and drugs in suicides. Br J Psychiatry 169:75–80PubMedCrossRef Öhberg A, Vuori E, Ojanperä I, Lönnqvist J (1996) Alcohol and drugs in suicides. Br J Psychiatry 169:75–80PubMedCrossRef
6.
go back to reference Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE (2007) Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. Eur J Clin Pharmacol 63:297–305PubMedCrossRef Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE (2007) Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. Eur J Clin Pharmacol 63:297–305PubMedCrossRef
7.
go back to reference Drummer OH (2007) Requirements for bioanalytical procedures in postmortem toxicology. Anal Bioanal Chem 388:1495–1503PubMedCrossRef Drummer OH (2007) Requirements for bioanalytical procedures in postmortem toxicology. Anal Bioanal Chem 388:1495–1503PubMedCrossRef
8.
go back to reference Druid H, Holmgren P (1997) A compilation of fatal and control concentrations of drugs in post-mortem femoral blood. J Forensic Sci 42:79–87PubMed Druid H, Holmgren P (1997) A compilation of fatal and control concentrations of drugs in post-mortem femoral blood. J Forensic Sci 42:79–87PubMed
9.
go back to reference Reis M, Aamo T, Ahlner J, Druid H (2007) Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J Anal Toxicol 31:254–264PubMed Reis M, Aamo T, Ahlner J, Druid H (2007) Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J Anal Toxicol 31:254–264PubMed
10.
go back to reference Koski A, Ojanperä I, Vuori E (2002) Alcohol and benzodiazepines in fatal poisonings. Alcohol Clin Exp Res 26:956–959PubMedCrossRef Koski A, Ojanperä I, Vuori E (2002) Alcohol and benzodiazepines in fatal poisonings. Alcohol Clin Exp Res 26:956–959PubMedCrossRef
11.
go back to reference Koski A, Ojanperä I, Vuori E (2003) Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol 22:281–287PubMedCrossRef Koski A, Ojanperä I, Vuori E (2003) Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol 22:281–287PubMedCrossRef
12.
go back to reference Koski A, Vuori E, Ojanperä I (2005) Relation of postmortem blood alcohol and drug concentrations in fatal poisonings involving amitriptyline, propoxyphene and promazine. Hum Exp Toxicol 24:389–396PubMedCrossRef Koski A, Vuori E, Ojanperä I (2005) Relation of postmortem blood alcohol and drug concentrations in fatal poisonings involving amitriptyline, propoxyphene and promazine. Hum Exp Toxicol 24:389–396PubMedCrossRef
13.
go back to reference Koski A, Vuori E, Ojanperä I (2005) Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Legal Med 119:344–348PubMedCrossRef Koski A, Vuori E, Ojanperä I (2005) Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Legal Med 119:344–348PubMedCrossRef
14.
go back to reference Vuori E, Ruohonen A, Penttilä A, Klaukka T, Lahti T (1989) Fatal poisonings with antidepressants in Finland 1985–1987. Acta Psychiatr Scand Suppl 354:55–60PubMedCrossRef Vuori E, Ruohonen A, Penttilä A, Klaukka T, Lahti T (1989) Fatal poisonings with antidepressants in Finland 1985–1987. Acta Psychiatr Scand Suppl 354:55–60PubMedCrossRef
15.
go back to reference Buckley NA, McManus PR (2002) Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332–1333PubMedCrossRef Buckley NA, McManus PR (2002) Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332–1333PubMedCrossRef
16.
go back to reference Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 184:41–47PubMedCrossRef Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 184:41–47PubMedCrossRef
17.
go back to reference Hoiseth G, Bramness JG, Christophersen AS, Morland J (2007) Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992–2003. Int J Legal Med 121:403–409PubMedCrossRef Hoiseth G, Bramness JG, Christophersen AS, Morland J (2007) Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992–2003. Int J Legal Med 121:403–409PubMedCrossRef
18.
go back to reference Strandell J, Bate A, Lindquist M, Edwards IR, The Swedish, Finnish, INteraction X-referencing Drug–Drug Interaction Database (the SFINX group) (2008) Drug–drug interactions—a preventable patient safety issue? Br J Clin Pharmacol 65:144–146PubMedCrossRef Strandell J, Bate A, Lindquist M, Edwards IR, The Swedish, Finnish, INteraction X-referencing Drug–Drug Interaction Database (the SFINX group) (2008) Drug–drug interactions—a preventable patient safety issue? Br J Clin Pharmacol 65:144–146PubMedCrossRef
19.
go back to reference Vuori E, Ojanperä I, Nokua J, Ojansivu RL (2006) Oikeuskemiallisesti todetut myrkytyskuolemat Suomessa vuosina 2002–2004. Suomen lääkärilehti (Finnish Medical Journal) 61:2339–2344 (in Finnish, English summary: fatal poisonings in Finland 2002–2004) Vuori E, Ojanperä I, Nokua J, Ojansivu RL (2006) Oikeuskemiallisesti todetut myrkytyskuolemat Suomessa vuosina 2002–2004. Suomen lääkärilehti (Finnish Medical Journal) 61:2339–2344 (in Finnish, English summary: fatal poisonings in Finland 2002–2004)
20.
go back to reference Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447–474PubMed Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447–474PubMed
21.
go back to reference Jack DB (ed) (1992) Handbook of clinical pharmacokinetic data. Macmillan, London, UK Jack DB (ed) (1992) Handbook of clinical pharmacokinetic data. Macmillan, London, UK
23.
go back to reference Jones AW, Holmgren P (2003) Comparison of blood–ethanol concentration in deaths attributed to acute alcohol poisoning and chronic alcoholism. J Forensic Sci 48:874–879PubMed Jones AW, Holmgren P (2003) Comparison of blood–ethanol concentration in deaths attributed to acute alcohol poisoning and chronic alcoholism. J Forensic Sci 48:874–879PubMed
24.
go back to reference Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH (2005) Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 28:67–80PubMedCrossRef Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH (2005) Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 28:67–80PubMedCrossRef
25.
go back to reference Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug–drug interactions in a large ambulatory population. J Manag Care Pharm 9:513–522PubMed Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug–drug interactions in a large ambulatory population. J Manag Care Pharm 9:513–522PubMed
26.
go back to reference Åstrand B, Åstrand E, Antonov K, Petersson G (2006) Detection of potential drug interactions—a model for a national pharmacy register. Eur J Clin Pharmacol 62:749–756PubMedCrossRef Åstrand B, Åstrand E, Antonov K, Petersson G (2006) Detection of potential drug interactions—a model for a national pharmacy register. Eur J Clin Pharmacol 62:749–756PubMedCrossRef
27.
go back to reference Gronroos PE, Irjala KM, Huupponen RK, Scheinin H, Forsstrom J, Forsstrom JJ (1997) A medication database—a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 53:13–17PubMedCrossRef Gronroos PE, Irjala KM, Huupponen RK, Scheinin H, Forsstrom J, Forsstrom JJ (1997) A medication database—a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 53:13–17PubMedCrossRef
28.
go back to reference Reynaud M, Petit G, Potard D, Courty P (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93:1385–1392PubMedCrossRef Reynaud M, Petit G, Potard D, Courty P (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93:1385–1392PubMedCrossRef
29.
go back to reference Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) (2000) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, PA Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) (2000) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, PA
30.
go back to reference Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed
31.
go back to reference Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide–citalopram or moclobemide–clomipramine overdoses. Lancet 342:1419PubMedCrossRef Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide–citalopram or moclobemide–clomipramine overdoses. Lancet 342:1419PubMedCrossRef
32.
go back to reference Vuori E, Henry JA, Ojanperä I, Nieminen R, Savolainen T, Wahlsten P, Jäntti M (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98:365–368PubMedCrossRef Vuori E, Henry JA, Ojanperä I, Nieminen R, Savolainen T, Wahlsten P, Jäntti M (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98:365–368PubMedCrossRef
33.
go back to reference Isbister GK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 17(187):361–365 Isbister GK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 17(187):361–365
34.
go back to reference Iwersen S, Schmoldt A (1996) Three suicide attempts with moclobemide. J Toxicol Clin Toxicol 34:223–225PubMedCrossRef Iwersen S, Schmoldt A (1996) Three suicide attempts with moclobemide. J Toxicol Clin Toxicol 34:223–225PubMedCrossRef
35.
36.
go back to reference Edoute Y, Nagachandran P, Svirski B, Ben-Ami H (2000) Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol 35:556–559PubMedCrossRef Edoute Y, Nagachandran P, Svirski B, Ben-Ami H (2000) Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol 35:556–559PubMedCrossRef
37.
go back to reference Verschraagen M, Koks CH, Schellens JH, Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin–verapamil. Pharmacol Res 40:301–306PubMedCrossRef Verschraagen M, Koks CH, Schellens JH, Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin–verapamil. Pharmacol Res 40:301–306PubMedCrossRef
38.
go back to reference Yarema MC, Becker CE (2005) Key concepts in postmortem drug redistribution. Clin Toxicol 43:235–241 Yarema MC, Becker CE (2005) Key concepts in postmortem drug redistribution. Clin Toxicol 43:235–241
39.
go back to reference Bauman JL, Didomenico RJ, Galanter WL (2006) Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 6:77–86PubMedCrossRef Bauman JL, Didomenico RJ, Galanter WL (2006) Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 6:77–86PubMedCrossRef
40.
go back to reference Cascorbi I (2003) Pharmcogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 33(Suppl 2):17–22PubMedCrossRef Cascorbi I (2003) Pharmcogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 33(Suppl 2):17–22PubMedCrossRef
Metadata
Title
Prevalence of adverse drug combinations in a large post-mortem toxicology database
Authors
Terhi Launiainen
Erkki Vuori
Ilkka Ojanperä
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
International Journal of Legal Medicine / Issue 2/2009
Print ISSN: 0937-9827
Electronic ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-008-0261-3

Other articles of this Issue 2/2009

International Journal of Legal Medicine 2/2009 Go to the issue

Editorial

Editorial